Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 18/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1380644 | 0.87 | GCK (0.66) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1426898 | 0.86 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL2656834 | 0.83 | GCK (0.52) | GCKKCNH2HRH3 | |
| SCHEMBL1380708 | 0.82 | GCK (0.61) | GCKKCNH2 | |
| SCHEMBL1426910 | 0.81 | GCK (0.61) | GCKKCNH2HRH3 | |
| SCHEMBL1378805 | 0.76 | GCK (0.72) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1492818 | 0.76 | GCK (0.78) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL12782058 | 0.76 | GCK (0.55) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL12782140 | 0.76 | GCK (0.66) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1377624 | 0.75 | GCK (0.75) | GCKKCNH2CYP1A2ABCB1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301929-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (Publ) (SE) | 2011-03-30 | — | — | EP | disclosed |